An interventional study of Snakehead Fish Extract and Curcumin in Lung Cancer (NSCLC), sponsored by Universitas Sumatera Utara. Completed at 1 site in Indonesia. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Universitas Sumatera Utara · Not applicable, Interventional, and Other
Background: Patients with advanced lung cancer receiving systemic therapy often experience nutritional decline, systemic inflammation, and impaired quality of life. Channa striata extract and Curcumin may offer complementary nutritional and anti-inflammatory support, but clinical evidence for their combination is limited.
The goal of this clinical trial is to learn if combined Channa striata (snakehead fish) extract and curcumin supplementation works to improve nutritional status, inflammation, and quality of life in adults with advanced lung cancer receiving systemic therapy. The main questions it aims to answer are:
Researchers will compare participants taking Channa striata extract plus curcumin to participants taking a placebo (a look-alike capsule that contains no active ingredients) to see if the co-supplementation works.
Participants will:
Patients with advanced lung cancer receiving systemic therapy frequently experience progressive weight loss, systemic inflammation, and impaired quality of life. Channa striata extract provides nutritional support rich in amino acids, while curcumin exerts anti-inflammatory properties. This study aims to evaluate whether the combination of Channa striata extract and curcumin as an adjunct to standard systemic therapy improves clinical and nutritional outcomes in adults with advanced lung cancer.
Participants receive either the combination supplement (3000 mg Channa striata extract and 300 mg curcumin daily) or a matching placebo for 9 weeks while continuing their standard systemic therapy. Clinical assessments are conducted at baseline and after 9 weeks to evaluate changes in body weight, nutritional status (body mass index and mid-upper arm circumference), systemic inflammatory markers (C-reactive protein, TNF-alpha, and IL-6), and health-related quality of life.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's enrollment of 60 is close to the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Universitas Sumatera Utara is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Snakehead Fish Extract and Curcumin
Participants in the intervention group received 2 capsules 3 times daily for 3 months (9 Weeks). Each capsule contained 500 mg of Channa striata extract and 50 mg of curcumin (Striatamin®; PT Mega Medica, Jakarta, Indonesia), providing a total daily dose of 3000 mg of C. striata extract and 300 mg of curcumin.
Change from baseline in body weight at 9 weeks
Body weight is measured in kilograms (kg) using a calibrated digital health scale at baseline and after 9 weeks of intervention. The metric is calculated as the post-intervention value minus the baseline value.
Time frame: Baseline and After 9 weeks
Change from baseline in serum C-reactive protein (CRP) levels at 9 weeks
Serum CRP levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in milligrams per deciliter (mg/dL).
Time frame: Baseline and After 9 weeks
Change from baseline in serum tumor necrosis factor-alpha (TNF-alpha) levels at 9 weeks
Serum TNF-alpha levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in picograms per milliliter (pg/mL).
Time frame: Baseline and After 9 weeks
Change from baseline in serum interleukin-6 (IL-6) levels at 9 weeks
Serum IL-6 levels are measured from venous blood samples using enzyme-linked immunosorbent assay (ELISA) and expressed in picograms per milliliter (pg/mL).
Time frame: Baseline and After 9 weeks
Change from baseline in mid-upper arm circumference (MUAC) at 9 weeks
MUAC is measured in centimeters (cm) on the relaxed left arm at the midpoint between the acromion and olecranon process using a non-elastic measuring tape.
Time frame: Baseline and After 9 weeks
Change from baseline in Body Mass Index (BMI) at 9 weeks
BMI is calculated as body weight in kilograms divided by height in meters squared (kg/m²).
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 functional scale scores at 9 weeks
Evaluates physical, role, emotional, cognitive, and social functioning using the EORTC QLQ-C30. Scores range from 0 to 100, where a higher score indicates a higher/better level of functioning.
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 symptom scale scores at 9 weeks
Evaluates symptoms including fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores range from 0 to 100, where a higher score indicates a higher level of symptoms or greater symptom burden.
Time frame: Baseline and After 9 weeks
Change from baseline in EORTC QLQ-C30 global health status score at 9 weeks
Assessed using the Indonesian version of the EORTC QLQ-C30 questionnaire. Global health status scores range from 0 to 100, where a higher score represents a better overall quality of life and higher level of general health.
Time frame: Baseline and After 9 weeks
Plan to share: No — The individual participant data (IPD) will not be shared to protect patient privacy and maintain the confidentiality of medical records, as approved by the Health Research Ethics Committee
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Jul 2026, 12 months.
Of 864 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's 12 months is below that.
Counting every sponsor, half of 915 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Sumatera Utara